News | January 03, 2014

American College of Cardiology Research Network Uses Big Data to Connect Practices With Trials

PINNACLE Registry to simplify data collection, help with patient identification

January 3, 2014 — The American College of Cardiology (ACC) has established the PINNACLE Registry Research Alliance to connect cardiovascular care teams with information about clinical trials and accelerate the systematic access of patients to potentially groundbreaking therapies.
Clinical trials are the gold standard for studying the effectiveness of new treatments, but difficulty in identifying eligible patients often limits the ability of researchers to conduct research studies worldwide.
The Research Alliance, which is open to nearly 2,500 cardiovascular professionals who are part of the outpatient PINNACLE Registry, will offer access to information about a range of research opportunities, expedite the identification of patients with the potential to benefit from participation in clinical trials and observational studies and support the advancement of up-and-coming researchers through investigator development programs.
“Registries in the ACC’s National Cardiovascular Data Registry [NCDR] have been valuable for providing feedback to the cardiovascular medical team to support quality improvement, and registry data has been analyzed for hundreds of observational research studies,” said John Harold, M.D., MACC and president, ACC. “The Research Alliance will allow the PINNACLE Registry to play a new role in shaping the future of cardiology by making it easier for more practices to participate in trials.”
Through the Research Alliance, information about clinical trials and potentially eligible patients identified through PINNACLE will be shared with their respective physicians. If physicians and their patients decide to partake in a research opportunity, the Alliance serves to reduce the participation burden for both practices and patients and potentially drive down costs associated with trial recruitment.
One of the first research studies in line to access the Alliance network is a clinical trial for an investigational drug in a new class of LDL-cholesterol modifying therapies, known as PCSK9 inhibitors. Recruitment for the phase 3 PCSK9 clinical trial program, ODYSSEY Outcomes, is underway and aims to include over 18,000 patients at 750 study locations worldwide.
“This exciting new program has the potential to expand treatment options for patients who are at risk for cardiovascular events,” said William Oetgen, M.D., MBA, FACC and executive vide president of science, education and quality, ACC. “The Research Alliance and its potential contributions to cardiovascular research represent another way ACC clinical registries contribute to the ACC’s mission to improve cardiovascular care.”
For more information:

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init